Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/27126
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDalli, Lachlan L-
dc.contributor.authorKim, Joosup-
dc.contributor.authorCadilhac, Dominique A-
dc.contributor.authorGreenland, Melanie-
dc.contributor.authorSanfilippo, Frank M-
dc.contributor.authorAndrew, Nadine E-
dc.contributor.authorThrift, Amanda G-
dc.contributor.authorGrimley, Rohan-
dc.contributor.authorLindley, Richard I-
dc.contributor.authorSundararajan, Vijaya-
dc.contributor.authorCrompton, Douglas E-
dc.contributor.authorLannin, Natasha A-
dc.contributor.authorAnderson, Craig S-
dc.contributor.authorWhiley, Leanne-
dc.contributor.authorKilkenny, Monique F-
dc.date2021-07-28-
dc.date.accessioned2021-08-02T05:47:33Z-
dc.date.available2021-08-02T05:47:33Z-
dc.date.issued2021-07-28-
dc.identifier.citationStroke 2021; 52(11): 3569-3577en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/27126-
dc.description.abstractAlthough a target of 80% medication adherence is commonly cited, it is unclear whether greater adherence improves survival after stroke or transient ischemic attack (TIA). We investigated associations between medication adherence during the first year postdischarge, and mortality up to 3 years, to provide evidence-based targets for medication adherence. Retrospective cohort study of 1-year survivors of first-ever stroke or TIA, aged ≥18 years, from the Australian Stroke Clinical Registry (July 2010-June 2014) linked with nationwide prescription refill and mortality data (until August 2017). Adherence to antihypertensive agents, statins, and nonaspirin antithrombotic medications was based on the proportion of days covered from discharge until 1 year. Cox regression with restricted cubic splines was used to investigate nonlinear relationships between medication adherence and all-cause mortality (to 3 years postdischarge). Models were adjusted for age, sex, socioeconomic position, stroke factors, primary care factors, and concomitant medication use. Among 8363 one-year survivors of first-ever stroke or TIA (44% aged ≥75 years, 44% female, 18% TIA), 75% were supplied antihypertensive agents. In patients without intracerebral hemorrhage (N=7446), 84% were supplied statins, and 65% were supplied nonaspirin antithrombotic medications. Median adherence was ≈90% for each medication group. Between 1% and 100% adherence, greater adherence to statins or antihypertensive agents, but not nonaspirin antithrombotic agents, was associated with improved survival. When restricted to linear regions above 60% adherence, each 10% increase in adherence was associated with a reduction in all-cause mortality of 13% for antihypertensive agents (hazard ratio, 0.87 [95% CI, 0.81-0.95]), 13% for statins (hazard ratio, 0.87 [95% CI, 0.80-0.95]), and 15% for nonaspirin antithrombotic agents (hazard ratio, 0.85 [95% CI, 0.79-0.93]). Greater levels of medication adherence after stroke or TIA are associated with improved survival, even among patients with near-perfect adherence. Interventions to improve medication adherence are needed to maximize survival poststroke.en
dc.language.isoeng-
dc.subjectantihypertensive agentsen
dc.subjectcerebral hemorrhageen
dc.subjectmedication adherenceen
dc.subjectmortalityen
dc.subjectsecondary preventionen
dc.subjectsurvivalen
dc.titleGreater Adherence to Secondary Prevention Medications Improves Survival After Stroke or Transient Ischemic Attack: A Linked Registry Study.en
dc.typeJournal Articleen
dc.identifier.journaltitleStrokeen
dc.identifier.affiliationAlfred Health, Melbourne, VIC, Australiaen
dc.identifier.affiliationSunshine Coast Clinical School, School of Medicine, Griffith University, Birtinya, QLD, Australiaen
dc.identifier.affiliationStroke and Ageing Research, Department of Medicine, School of Clinical Sciences at Monash Health, Central Clinical School, Monash University, VIC, Australiaen
dc.identifier.affiliationPeninsula Clinical School, Central Clinical School, Monash University, VIC, Australiaen
dc.identifier.affiliationDepartment of Neuroscience, Central Clinical School, Monash University, VIC, Australiaen
dc.identifier.affiliationOxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, United Kingdomen
dc.identifier.affiliationNuffield Department of Population Health, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, United Kingdomen
dc.identifier.affiliationSchool of Population and Global Health, The University of Western Australia, Perthen
dc.identifier.affiliationFaculty of Medicine and Health, The University of Sydney, NSW, Australiaen
dc.identifier.affiliationDepartment of Public Health, La Trobe University, Bundoora, VIC, Australiaen
dc.identifier.affiliationDepartment of Neurology, Northern Health, Epping, VIC, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Sydney, NSW, Australiaen
dc.identifier.affiliationThe George Institute for Global Health, Peking University Health Science Center, Chinaen
dc.identifier.affiliationRockhampton Hospital, QLD, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Healthen
dc.identifier.doi10.1161/STROKEAHA.120.033133en
dc.type.contentTexten
dc.identifier.pubmedid34315251-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Dec 24, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.